The Danish stock market is buzzing with rumours that Danish-American biotech company Genmab is close to entering a lucrative new partnership agreement, reports national daily newspaper Berlingske Tidende. A year ago, Genmab entered a major partnership agreement with GlaxoSmithKline (GSK) for HuMax CD20 worth DKK 12 bn (USD 2.4 bn).
Genmab's IR manager Helle Husted is not denying that a new agreement could be on the way for HuMax EGFr, a drug candidate being developed for the treatment of head and neck cancer as well as lung cancer. Husted says however that the company is in no hurry and can wait until it has received data from a phase III study of the drug, scheduled for 2008.
"Having said that, we would not say no if a good offer comes along. The door is not closed to negotiations, and they are ongoing with several parties at the moment. We have not mentioned any figures either. That would be silly of us," Helle Husted said.
Genmab MD Lisa Drakeman said to Berlingske Business about a month ago that 'HuMax EGFr is on a market which is still growing. It has clear blockbuster potential with world sales measured in billions."
Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, rheumatoid arthritis, infectious diseases and other inflammatory conditions. Genmab is listed on the C20 index of the OMX Nordic Exchange Copenhagen.